MANE · Veradermics, Inc · Metrics
$124.39
-0.47 (-0.38%)
At close · Nov 19
Return incl. dividend (before tax)
Market Cap
$5.25B
Shares
42.20M
Volume · Nov 19
293.74K
Avg daily vol (3M)
739.62K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
MANE metrics
64 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$124.39
Market cap
$5.25B
Price action
23 metricsPrice change (1W)
-8.1%
Price change (30D)
-2.1%
Price change (3M)
+18.1%
Price change (6M)
+18.8%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
91.9%
Annualized volatility (3M)
72.5%
Implied volatility (30D)
57.5%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.2
RSI (14D)
44.9
Price vs SMA 50
+0.1%
Price vs SMA 200
+28.3%
Avg volume (3M)
739,617
Relative volume
0.4
Average dollar volume
$88.36M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
42.20M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.6
reciprocal yield 15.2%
FCF yield
-1.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-10-19
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$111.20M
Net income (TTM)
−$93.58M
Trailing 12 months
Diluted EPS (TTM)
$-40.18
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5,526.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-11.7%
Return on assets
-11.6%
Debt / equity
0.0
Current ratio
77.7
EBITDA (TTM)
—
Free cash flow (TTM)
−$82.60M
Quick ratio
77.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$132.16M
Latest balance sheet
Cash & equivalents
$132.16M
Total assets
$807.22M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$82.23M
Capital expenditures (TTM)
$372,000
R&D (TTM)
$73.80M
SG&A (TTM)
—
Stock compensation (TTM)
$13.84M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
208
13F filer change QoQ
+43
Institutional ownership
86.3%
Conviction holders (share of 13F filers)
2.9%
Crowding (high-turnover and private-fund holders)
41.2%
Private-fund adviser ownership
37.7%
Active holders' share change QoQ
+4.9%
Holder tenure
2.8
Price vs estimated holder cost
+63.3%
Ownership (registered funds)
1 metricsIndex-fund ownership
5.4%
Short interest
3 metricsShort interest
8.0%
Latest settlement · 5.1 days to cover
Days to cover
5.1d
Short-squeeze score
70 / 100
Insider activity
2 metricsNet insider buying (90D)
−$75.19M
Insider-sentiment score
15 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1827635
CUSIP
922967104
13F (30d)
201 filings
198 filers
Visit website
Investor relations